ライフサイエンスコーパス: A(3) receptor

1 a modulator of cell growth (mainly acting at A3 receptors).

2 e is not coupled to the xanthine-insensitive A3 receptor.

3 e cardioprotective role of a novel adenosine A3 receptor.

4 ture MDDCs as native expressers of the human A3 receptor.

5 AB-MECA binding confirmed the site to be the A3 receptor.

6 effect that is mediated by adenosine A1 and A3 receptors.

7 and which had a Ki value of 248 nM at human A3 receptors.

8 yl analogue was clearly less potent at human A3 receptors.

9 to enhance potency and selectivity at human A3 receptors.

10 gues were nearly equipotent at rat and human A3 receptors.

11 1 and A2A receptors and at recombinant human A3 receptors.

12 measurable affinity at adenosine A1, A2A, or A3 receptors.

13 ne) has high affinity for recombinant A1 and A3 receptors.

14 ting the presence of phospholipase C-coupled A3 receptors.

15 e, genistein, also bound only very weakly at A3 receptors.

16 receptors, respectively, and 3.0 nM at human A3 receptors.

17 m intracellular stores via the activation of A3 receptors.

18 thesized and found to be selective for human A3 receptors.

19 ed to arginine, the homologous amino acid in A3 receptors.

20 dioligands to recombinant canine A1, A2A, or A3 receptors.

21 t A1 and A2A receptors and 3 microM at human A3 receptors.

22 wed 14-fold greater affinity at human vs rat A3 receptors.

23 r affinity but 15-fold selectivity for human A3 receptors.

24 tors, respectively, and 3.25 microM at human A3 receptors.

25 increased selectivity of flavonols for human A3 receptors.

26 (Ki = 14 nM), while it lacks affinity at rat A3 receptors.

27 , had Ki values of 0.3 - 0.4 microM at human A3 receptors.

28 5-ethyl diester was > 600-fold selective for A3 receptors.

29 l cyclase in CHO cells expressing cloned rat A3 receptors.

30 the anti-ischemic effect of adenosine A1 and A3 receptors.

31 chieve the anti-ischemic effect of adenosine A3 receptors.

32 its complete selectivity toward A1, A2A, and A3 receptors.

33 Neither cells expressed A1 or A3 receptors.

34 selective enhancement of agonist binding at A3 receptors.

35 transfected with a vector encoding the human A(3) receptor.

36 transfected with the human adenosine A(1) or A(3) receptor.

37 evels of selectivity for the human adenosine A(3) receptor.

38 ffect in the heart via activation of A(1) or A(3) receptors.

39 otent than the (4S,2'R)-isomer in binding to A(3) receptors.

40 ions failed to improve potency in binding at A(3) receptors.

41 d a progressive reduction in the affinity at A(3) receptors.

42 ically to modify ligand affinity at A(1) and A(3) receptors.

43 losteric modulator of the adenosine A(1) and A(3) receptors.

44 tors, with no involvement of A(1), A(2B), or A(3) receptors.

45 protein for A(2A) and A(2B), but not A(1) or A(3) receptors.

46 ced lung mast cell degranulation by engaging A(3) receptors.

47 er to the 3-position lowered the affinity at A3 receptors 3-fold.

48 of a mutant (R108A, R3.50A) of the adenosine A(3) receptor (A(3) AR) to that of the wild-type recepto

49 The adenosine A(3) receptor (A(3)AR) is a G protein-coupled receptor (

50 The adenosine-A(3) receptor (A(3)AR) is a G protein-coupled receptor t

51 re, we developed a photoswitchable adenosine A(3) receptor (A(3)R) agonist that confers optical contr

52 denosine A(1) receptor (A(1)R) and adenosine A(3) receptor (A(3)R) based on an orthosteric antagonist

53 The adenosine A(3) receptor (A(3)R) belongs to a family of four adenos

54 The adenosine A(3) receptor (A(3)R) binds adenosine and is a drug targ

55 The A(3) receptor (A(3)R) was found to be expressed in eosin

56 onstrate a pivotal contribution of adenosine A(3) receptor (A(3)R)-mediated signaling to the TLR4-ind

57 e contribution of A(1) receptors (A(1)R) and A(3) receptors (A(3)R) is not known.

58 cological or genetic inactivation of the ADO A(3) receptor, A(3)R, prevents CXCL16 effect.

59 ctivity and stability of the human adenosine A3 receptor (A3) were investigated.

60 previous work, using a fluorescent adenosine-A3 receptor (A3AR) agonist and fluorescence correlation

61 Adenosine A3 receptor (A3AR) having an identical N-terminal region

62 tion and degranulation of mast cells via the A3 receptor (A3AR).

63 Thus, adenosine A2B and A3 receptors act in a functional cooperative fashion to

64 ized adenosine in mice occur largely through A(3) receptor activation and that mast cells contribute

65 eptors was employed as a functional index of A3 receptor activation.

66 The A3 receptor (ADORA3) was expressed only in mouse islets

67 etalloproteinase (MMP)2, MMP7, and adenosine A3 receptor (ADORA3).

68 oropropyl ester (26) was favorable for human A3 receptor affinity, resulting in Ki values of 4.2 and

69 s in vivo was tested by exposing mice to the A(3) receptor agonist, IB-MECA.

70 nophils with the highly potent and selective A3 receptor agonist CI-IB-MECA clearly induced Ca2+ rele

71 BK-induced responses were unaffected by the A3 receptor agonist IB-MECA (1 microM).

72 2-chloro-N6-cyclopentyladenosine (CCPA) and A3 receptor agonist N6-(3-iodobenzyl)-adenosine-5'-N-met

73 In addition, the A3 receptor agonist N6-(3-iodobenzyl)adenosine-5'-N-meth

74 ophil membranes were characterized using the A3 receptor agonist radioligand 125I-labeled AB-MECA, wh

75 terized the actions of a selective adenosine A3 receptor agonist, 2-chloro-N6-(3-lodobenzyl)-adenosin

76 lopentyladenosine and not with the selective A3-receptor agonist 4-aminobenzyl-5'-N methylcarboxamido

77 d reduced affinity for most of the uncharged A(3) receptor agonists and antagonists examined.

78 general approach for the design of A(1) and A(3) receptor agonists having favorable pharmacodynamic

79 Selective A(1) and A(3) receptor agonists were shown to activate phospholip

80 new binary conjugates of adenosine A(1) and A(3) receptor agonists were synthesized and tested in a

81 t of the concentration-response curve of the A3 receptor agonists in the presence of antagonist and,

82 ist 2-Chloro-N6-cyclopentyladenosine and the A3 receptor agonists N6-Benzyl-NECA and 1-deoxy-1-[6-[[(

83 gineered atrial cells, in which either human A(3) receptors alone or both human A(1) and A(3) recepto

84 olin-5-yl]benzene acetamide (MRS1220) at the A(3) receptor and xanthine amine congener (XAC) and XAC-

85 Activation and blockade of adenosine A(2b)/A(3) receptors and activation and inhibition of protein

86 ly selective for the A(2A) over the A(1) and A(3) receptors and were more potent than MRE-0470 and CG

87 ryonic kidney 293 cells expressing the human A3 receptor and a chimeric Galphaq-i3 protein, which was

88 it is natural to consider a link between the A3 receptor and eosinophils.

89 ocytes with enhanced expression of the human A3 receptor and showed significantly higher ATP content,

90 tive, 28, displayed a Ki value of 31.4 nM at A3 receptors and 1300-fold selectivity vs A1 receptors.

91 Cardiac atrial cells lack native A3 receptors and exhibit a shorter duration of cardiopro

92 nd the compound is thus nonselective between A3 receptors and L-type Ca2+ channels.

93 44, displayed a Ki value of 7.94 nM at human A3 receptors and selectivity of 5200-fold.

94 poxia, ischemia, or seizures), activation of A3 receptors and subsequent heterologous desensitization

95 displayed a Ki value of 4.8 microM at human A3 receptors and was inactive at rat A1/A2a receptors.

96 13, displayed a Ki value of 0.59 nM at human A3 receptors and was moderately selective for that subty

97 antagonists of competitive binding at human A3 receptors, and K(i) values ranging from 120 nM to 101

98 , 3, which had a Ki value of 7.7 nM at human A3 receptors, and was 40- and 14-fold selective vs rat A

99 layed the highest potency and selectivity as A(3) receptor antagonist (K(i) = 258 nM).

100 ethyluronamide (Cl-IB-MECA), and a selective A3 receptor antagonist, 3-ethyl-5-benzyl-2-methyl-4-phen

101 Among the synthesized compounds, selective A(3) receptor antagonists were found.

102 etabotropic glutamate receptor 1 (mGluR1) or A(3) receptor antagonists, indicating a role for both gl

103 levels after OGD was prevented by mGluR1 or A(3) receptor antagonists, indicating that AMPARs are de

104 potent as other recently reported, selective A(3) receptor antagonists; however, they display uniquel

105 ceptor antagonist CGS15943, but not by A1 or A3 receptor antagonists.

106 Adenosine A(3) receptors are of interest in the treatment of cardi

107 e signaling pathways activated by the A1 and A3 receptors are distinct and involve selective coupling

108 Thus, adenosine A1 and A3 receptors are linked to different G-proteins.

109 Since rodent adenosine A3 receptors are not blocked by theophylline, selective

110 he rat and human adenosine A1, A2A, A2B, and A3 receptors are presented.

111 Rodent A3 receptors are relatively insensitive to xanthines; in

112 early a3-subunit-containing GABA(A) (GABA(A)a3) receptors are a key developmental organizer.

113 upregulation; (2) the A2a, but not the A1 or A3, receptors are the major expressed and functionally c

114 adenosine receptors, but not A(2B), A(1), or A(3) receptors, are shown to be mostly responsible for e

115 peripheral blood eosinophils express the ADO A3 receptor as indicated by detection of the transcript

116 imidazo[2.1-i]pur in-5-one (PSB-11) from the A3 receptors, as well as [3H]N6-[(R)-phenylisopropyl]ade

117 ed the effects of an agonist in a functional A3 receptor assay, i.e. inhibition of adenylyl cyclase i

118 made synthetic ligands, we mutated the human A(3) receptor at the site of a critical His residue in T

119 ion constant (K(i)) value of 219 nM at human A(3) receptors (binding of [(125)I]AB-MECA (N(6)-(4-amin

120 ), may be substituted with L (present in the A3 receptor) but not with D (in biogenic amine receptors

121 ic and electrostatic regions with the A1 and A3 receptors, but not the A2A.

122 us, co-activation of both adenosine A(1) and A(3) receptors by the binary A(1)/A(3) agonists represen

123 nyl or 3-furyl group reduced the affinity at A3 receptors by 4- and 9-fold, respectively.

124 ding pyridine derivative reduced affinity at A3 receptors by 88-fold and slightly increased affinity

125 A novel adenosine A3 receptor can mediate this protective function.

126 Also, increased expression of the A3 receptor caused an enhanced cardioprotective effect b

127 cells with cDNA encoding the human adenosine A3 receptor causes a sustained A3 agonist-mediated cardi

128 y transfected with the human adenosine A1 or A3 receptor cDNA individually or they were cotransfected

129 ene transfer and overexpression of the human A3 receptor cDNA, renders the myocytes resistant to the

130 at least two populations of agonist-occupied A3-receptor complexes, showing different motilities with

131 and antagonists suggested that activation of A(3) receptors could induce mast cell histamine release

132 eness to aerosolized adenosine in wild-type, A(3) receptor-deficient, and mast cell-deficient mice.

133 ty at the H272E mutant relative to wild-type A(3) receptors, depending on the position of the amino g

134 with xanthines allows selective detection of A3 receptors despite the lack of selectivity of the liga

135 degree of selectivity for cloned human brain A3 receptors, determined in competitive binding assays v

136 rative interactions between protomers of the A(3)-receptor dimer in single living cells.

137 , and adenosine for the ABA-X-BY630-occupied A(3)-receptor dimer yielded values of 6.0 +/- 0.1, 5.9 +

138 ism combined with high functional potency at A(3) receptors (EC(50) < 1 nM) may produce tissue select

139 e protection mediated by prior activation of A3 receptors exhibits a significantly longer duration th

140 t of timing of hypertonic saline exposure on A3 receptor expression and degranulation was studied in

141 myl methionyl-leucyl-phenylalanine inhibited A3 receptor expression and degranulation, whereas hypert

142 l-leucyl-phenylalanine-stimulation augmented A3 receptor expression and degranulation.

143 Polymorphonuclear neutrophil A3 receptors expression determines whether hypertonic sa

144 ence that semaphorins, activating the Plexin-A3 receptor, function as retraction inducers to trigger-

145 covalent antagonist for the human adenosine A(3) receptor (hA(3)AR).

146 Antagonism of the human adenosine A(3) receptor (hA(3)R) has potential therapeutic applica

147 ine-2,4-dione derivatives as human adenosine A3 receptor (hA3R) antagonists to determine their kineti

148 In the CA1 region, activation of A3 receptors had no direct effects on synaptically evoke

149 ding of flavonoids to adenosine A1, A2A, and A3 receptors has been conducted using comparative molecu

150 e renal tubular epithelium, A(1), A(2A), and A(3) receptors have all been identified as playing a rol

151 enosine receptor subtypes, A1, A2A, A2B, and A3 receptors, have been cloned and characterized.

152 At A1, A2A, and A3 receptors however the optimum occurs with four methyl

153 Activation of both endogenous A(1) and A(3) receptors in ventricular myocytes resulted in a pro

154 The function of A(3) receptors in vivo was tested by exposing mice to th

155 criminating hydrophobic region occurs in the A3 receptor in proximity to the N5-substituent.

156 pt that an increased expression of the human A3 receptor in the cardiac myocyte can be an important c

157 indicated by detection of the transcript for A3 receptors in polymerase chain reaction-amplified cDNA

158 d high specific activity, the low density of A3 receptors in rat brain appears insufficient to allow

159 ful for localization and characterization of A3 receptors in rat brain.

160 Therefore, involvement of ADO A3 receptors in the bronchoconstrictor and/or inflammato

161 eted using a rhodopsin-based model of ligand-A(3) receptor interactions.

162 The A3 receptor is coupled via RhoA to activate phospholipas

163 The adenosine A3 receptor is expressed in brain, but the consequences

164 ovides the first evidence that the adenosine A3 receptor is present on ventricular myocytes and can m

165 way, suggesting that selective activation of A3 receptors is an effective means of protecting the isc

166 Thus, activation of both A1 and A3 receptors is required to mediate the cardioprotective

167 confirm that adenosine, acting at A(2A) and A(3) receptors, is a potent regulator of inflammation.

168 e in radioligand binding assays for A(1) and A(3) receptors (K(i) values of 0.7-3.5 nm) versus A(2A)

169 selective (approximately 200-fold) for human A3 receptors (Ki = 0.56 microM).

170 wild-type mice, but not in those of A(2A) or A(3) receptor knockout mice.

171 in wild-type mice while having no effect in A(3) receptor knockout mice.

172 lammation in an air-pouch model in A(2A) and A(3) receptor knockout mice.

173 ) receptor knockout), A(3)AR(-/-) (adenosine A(3) receptor knockout), and eNOS(-/-) (endothelial nitr

174 ertonic saline resuscitation was assessed in A3 receptor knockout and wild-type mice.

175 Mortality in A3 receptor knockout mice remained only 50% regardless o

176 ed hypertonic saline-treatment was absent in A3 receptor knockout mice.

177 onists that activate both adenosine A(1) and A(3) receptors may thus prove beneficial for the treatme

178 Here we investigated whether A3 receptors may diminish the efficacy of hypertonic sal

179 e affinity of flavones at both rat and human A3 receptors may explain some of the previously observed

180 y of neonatal mononuclear cells to adenosine A3 receptor-mediated accumulation of cAMP, a second mess

181 ominant negative RhoA (RhoAT19N) blocked the A3 receptor-mediated phospholipase D activation and card

182 I870R preferentially inhibited the human A3 receptor-mediated protection from ischemia.

183 The study indicates that cardiac adenosine A3 receptor mediates a sustained cardioprotective functi

184 s as TNF-alpha inhibitors suggested that the A3 receptor might be involved (N6-(3-iodobenzyl)-9-[5-(m

185 hypothesis, using a previously derived human A(3) receptor model, shows the bulkier of the two ester

186 uced by coexpression of a nonbinding (N250A) A(3)-receptor mutant.

187 the (S)-analogue, particularly at the human A(3) receptor (N/S affinity ratio of 150).

188 In binding assays at A(1), A(2A), and A(3) receptors, (N)-methanocarba-adenosine was of higher

189 -356 nM), and heteromeric GluA1/A2 and GluA2/A3 receptors nonselectively, with IC(50) values in the m

190 A3 receptors on eosinophil membranes were characterized

191 These results attest to the existence of ADO A3 receptors on eosinophils and suggest that ADO stimula

192 The effect of A3 receptors on the efficacy of hypertonic saline resusc

193 Moreover, activation of A(2b)/A(3) receptors or activation of PKCepsilon prevented deg

194 n the dissociation kinetics of 125I-ABA from A3 receptors or [125I]-[2-(4-amino-3-iodo-phenyl)ethylam

195 r cells expressing native adenosine A(1) and A(3) receptors, or engineered atrial cells, in which eit

196 The specificity of the A(3) receptor-phospholipase D interaction was also demon

197 Activation of adenosine A1 or A3 receptors protects heart cells from ischemia-induced

198 ease and autocrine feedback through P2Y2 and A3 receptors provide signal amplification, controlling g

199 by > 95%, indicating that xanthine-resistant A3 receptors represent a quantitatively minor subtype.

200 uman A(2B) receptors versus human A(1)/A(2A)/A(3) receptors, respectively, and 8.5- and 310-fold sele

201 ivative had K(i) values of 4.1 and 2.2 nM at A(3) receptors, respectively, and were highly selective

202 pounds are potent agonists at either A(1) or A(3) receptors, respectively, were synthesized.

203 Ki values of 41.3 and 1.90 microM at A1 and A3 receptors, respectively, and was inactive at A2A rece

204 hich was less potent than 27 at A1, A2A, and A3 receptors, retained moderate potency at A2B receptors

205 ibution of neural adenosine A1, A2a, A2b, or A3 receptors (Rs) in the human intestine was investigate

206 of the 6-phenyl substituent was tolerated in A3 receptor selective agents.

207 The adenosine A3 receptor-selective antagonist 3-ethyl 5-benzyl-2-meth

208 Inclusion of a 6-phenyl group enhanced A3 receptor selectivity: Compound 28 (MRS1097; 3,5-dieth

209 These data suggest that A(3) receptor signaling is key to adenosine-mediated STA

210 The A3 receptor signals via RhoA and phospholipase D (PLD) t

211 ine (BW-A1433), an antagonist of A1, A2, and A3 receptors, significantly reduced the vasoconstrictor

212 binary agonist MRS 1741 coactivated A(1) and A(3) receptors simultaneously, with full cardioprotectio

213 silon and ALDH2 were both activated by A(2b)/A(3) receptor stimulation in HMC-1, and PKCepsilon inhib

214 Further, RAW 264.7 A(3) receptor stimulation with Cl-IB-MECA reduces IFN-ga

215 each being selective for either the A(1) or A(3) receptor subtype.

216 eceptors with particular selectivity for the A3 receptor subtype.

217 led in myocytes cotransfected with the human A3 receptor than in those cells expressing the human A1

218 3-keto derivative was 5-fold more potent at A3 receptors than a related open-ring analogue.

219 ne ring, esters were much more selective for A3 receptors than closely related thioester, amide, and

220 al myocytes (which do not express endogenous A(3) receptors) that had been transfected with a vector

221 At the A(3) receptor, this could be markedly increased by both

222 A3 receptor transcript was substantially diminished, and

223 ogue was shown to increase affinity at human A(3) receptors upon oxidation from the 1-methyl-1,4-dihy

224 was determined at cloned human and rat brain A3 receptors using [125I]-AB-MECA [N6-(4-amino-3-iodoben

225 Affinity was determined at cloned human A3 receptors using [125I]AB-MECA (N6-(4-amino-3-iodobenz

226 inity was determined at cloned human and rat A3 receptors using [125I]AB-MECA [N6-(4-amino-3-iodobenz

227 inity was determined at cloned human and rat A3 receptors using [125I]AB-MECA [N6-(4-amino-3-iodobenz

228 one visnagin was 30-fold selective for human A3 receptors vs either rat A1 or A2A receptors.

229 o bind with 14-17-fold selectivity for human A3 receptors vs rat A1 and A2A receptors, with a Ki valu

230 A reduction in XAC potency at the A(1) and A(3) receptor was achieved within 1 min of Brilliant Bla

231 ngener (XAC) and XAC-X-BY630 at the A(1) and A(3) receptors was significantly decreased in the presen

232 A rhodopsin-based model of the human A3 receptor was built, and the pyridine reference ligand

233 umulation in intact cells that express human A3 receptors was employed as a functional index of A3 re

234 ioligand binding by BTH4 (7) at cloned human A3 receptors was negligible but one slightly A3 selectiv

235 , whereas messenger RNA expression of A1 and A3 receptors was reduced (both, p = .03).

236 erivative, 26, with a Ki value of 58.3 nM at A3 receptors, was > 1700-fold selective vs either A1 rec

237 tive, 24, with a Ki value of 0.670 microM at A3 receptors, was 24-fold selective vs A1 receptors (Ki

238 rate constants of ABA-X-BY630 from A(1) and A(3) receptors were 1.45 +/- 0.05 and 0.57 +/- 0.07 min(

239 s having mixed selectivity for both A(1) and A(3) receptors were created through the covalent linking

240 A(3) receptors alone or both human A(1) and A(3) receptors were expressed.

241 oned media was maximal if both HMC-1 A2B and A3 receptors were activated, whereas activation of A2B r

242 and A(2B) adenosine receptors but not in the A(3) receptor, which is cerebroprotective and cardioprot

243 cover a signaling cascade initiated by A(2b)/A(3) receptors, which triggers PKCepsilon-mediated ALDH2

244 Inhibition of the adenosine A(3) receptor with a subtype-specific antagonist (MRS 11

245 f the adenosine A1 receptor with CCPA or the A3 receptor with C1-IB-MECA can replace preconditioning

246 However, activation of A3 receptors with Cl-IB-MECA antagonized the adenosine A

247 quinazolin-5-amine (CGS15943) binds to human A3 receptors with high affinity (Ki = 14 nM), while it l

248 ) binds nonselectively to human A1, A2A, and A3 receptors with high affinity.

249 lectron-withdrawing groups were specific for A3 receptors with nanomolar Ki values and selectivity as

250 derivative was the most potent derivative at A3 receptors, with a Ki value of 0.36 nM.

251 carboxylate , 38, was highly potent at human A3 receptors, with a Ki value of 20 nM.

252 tive and highly potent at both human and rat A3 receptors, with Ki values of 18.9 and 113 nM, respect